Search Site

Cheryl H. Waters, MD

  • Albert B. and Judith L. Glickman Professor of Neurology at CUMC
Cheryl H. Waters, MD

Cheryl Waters MD FRCP(C), holds bachelors and masters degrees in Pharmacology from the University of Toronto, where she studied dopamine receptor function with Philip Seeman. She completed medical school at University of Toronto, an internship at University of Chicago, and returned to Toronto for Internal Medicine, Neurology and a fellowship in Clinical Pharmacology. She moved to California and developed the Movement Disorder Program at the University of Southern California. Dr. Waters then moved to New York to take on her current position as Chief of Clinical Practice and Services in the Division of Movement Disorders. She has been involved in research on the genetics of Parkinson's disease and the treatment of this disorder. She has authored numerous articles and book chapters and a book just printed in its sixth edition: Diagnosis and Management of Parkinson's Disease. She has been an investigator in numerous studies involving a variety of new medical and surgical treatments. She is the first to hold the Albert B. and Judith L. Glickman Chair in Neurology.

Departmental Appointments

  • Department of Neurology
    Division of Movement Disorders

Board Certifications

  • Neurology

Areas of Expertise

  • Parkinson's Disease
  • Movement Disorder

Education & Training

  • University of Toronto Faculty of Medicine
  • Residency: University of Toronto Hospitals
  • Fellowship: University of Toronto Hospitals

Locations

  • Neurological Institute of New York

    710 West 168th Street
    Floor: 3
    New York, NY 10032
    Phone:
    (212) 305-3665
    For new and current patient appointments, call:
    (212) 305-1303
    Fax:
    (212) 305-1304
  • ColumbiaDoctors Tarrytown

    155 White Plains Road
    Suite: W100
    Tarrytown, NY 10591
    Phone:
    (914) 366-4200
    For new and current patient appointments, call:
    (914) 366-4200

Practices And Centers

  • ColumbiaDoctors Tarrytown

Provider Affiliations

  • NewYork-Presbyterian/Columbia

Insurance Programs

Please contact the provider's office directly to verify that your particular insurance is accepted.

  • AARP [Medicare Managed Care]
  • Aetna [EPO, HMO, Medicare Managed Care, NY Signature, POS, PPO, Signature Administrators, Student Health]
  • Affinity [Access (Exchange), Essential Plan, Medicaid Managed Care, Medicare Managed Care]
  • Amida Care [Special Needs Plan]
  • Blue Shield [New Jersey]
  • Cigna [EPO, Great West, HMO, POS, PPO]
  • Empire Blue Cross Blue Shield [Blue Priority, EPO, HMO, Indemnity, Medicare (Mediblue), Medicare Managed Care, NYP Employee Plan, Pathway (Exchange), POS, PPO]
  • Empire Blue Cross Blue Shield HealthPlus [Child/Family Health Plus, Essential Plan, Medicaid Managed Care]
  • Fidelis Care [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]
  • Healthfirst [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]
  • Local 1199 [Local 1199]
  • MagnaCare [MagnaCare]
  • Medicare [Traditional Medicare (NY)]
  • Oxford Health Plans [Freedom, Liberty, Medicare Managed Care]
  • POMCO [POMCO]
  • UnitedHealthcare [Columbia University Employee Plan, EPO, Essential Plan, HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]
  • VNSNY CHOICE [SelectHealth]
  • WellCare [Medicaid Managed Care, Medicare Managed Care]

This provider accepts new patients

Appointment Phone Number: (212) 305-1303

NIH Grants

  • MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF GZ/SAR402671 IN PATIENTS WITH EARLY-STAGE PARKINSON''S DISEASE CARRYING A GBA MUTATION OR OTHER PRESPECIFIED VARIANT (P&S Industry Clinical Trial)

    Jun 1 2017 - Jun 30 2022

    A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY INVESTGATING THE EFFICACY AND SAFETY OF CVT 301 (LEVODOPA INHALATION POWDER) IN PARKINSON''S DISEASE PATIENTS WITH MOTOR RESPONSE FLUCTUATIONS (OFF PHENOMENA) (P&S Industry Clinical Trial)

    Apr 1 2015 - Apr 1 2020

    " A PHASE 3, 12-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFICACY OF ORAL ISTRADEFYLLINE 20 AND 40 MG/DAY AS TREATMENT FOR SUBJECTS WITH MODERATE TO SEVERE PARKINSON''S DISEASE" (P&S Industry Clinical Trial)

    Apr 25 2014 - Apr 25 2019

    CLINICAL COORDINATION CENTER FOR STEADY-PD3 (Federal Gov)

    Aug 1 2014 - Mar 31 2019

    PHASE 3 TRIAL OF INOSINE FOR PARKINSON S DISEASE CCC (Federal Gov)

    Sep 1 2015 - Jun 30 2017

    SETTLE EXT 28850 (P&S Industry Clinical Trial)

    Dec 14 2011 - Dec 14 2016

    MOTION EXT (P&S Industry Clinical Trial)

    Oct 11 2011 - Oct 11 2016

    SYN115-CL02 (P&S Industry Clinical Trial)

    Jun 28 2011 - Jun 28 2016

    A PHASE 3, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED DOSERANGE-FINDING EFFICACY AND SAFETY STUDY OF PRELADENANT IN (P&S Industry Clinical Trial)

    Jan 21 2011 - Jan 21 2016

    OPEN-LABEL, 12-MONTH SAFETY AND EFFICACY STUDY OF LEVODOPA- CARBIDOPA INTESTINAL GEL IN LEVODOPA-RESPONSIVE PARKINSON"S (P&S Industry Clinical Trial)

    Dec 15 2010 - Dec 15 2015

    A PHASE III, DOUBLE-BLIND,PLACEBO-CONTROLLED,RANDOMISED TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF A DOSE RANGE OF 50 (P&S Industry Clinical Trial)

    Nov 11 2010 - Nov 11 2015

    AFQ056A2216- (P&S Industry Clinical Trial)

    Aug 23 2010 - Aug 23 2015

    A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMISED TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF A LOW AND HIGH (P&S Industry Clinical Trial)

    Jul 29 2010 - Jul 29 2015

    OPEN-LABEL CONTINUATION TREATMENT STUDY WITH LEVODOPA INSTESTINAL GEL IN SUBJECTS WITH ADVANCED PARKINSON"S DISEASE AND (P&S Industry Clinical Trial)

    Jun 15 2010 - Jun 15 2015

    AN OPEN LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX066 IN SUBJECTS WITH PARKINSON"S DISEASE (P&S Industry Clinical Trial)

    Sep 8 2010 - Jun 8 2015

    A STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IPX066 IN ADVANCED PARKING''S DISEASE (P&S Industry Clinical Trial)

    Nov 16 2009 - Nov 16 2014

    A PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IPX066 IN SUBJECTS WITH PARKINSON''S DISEASE (P&S Industry Clinical Trial)

    May 21 2009 - May 21 2014

    SOLVAY -- S187 3 004 (P&S Industry Clinical Trial)

    Jun 13 2008 - Jun 30 2012

    SCHWARTZ BIOS--SP921 (P&S Industry Clinical Trial)

    Dec 4 2007 - Jun 30 2012

    A RANDOMOZED,DOUBLE-BLIND,DOUBLE-DUMMY, EFFICACY, SAFETY ANDTOLERABILITY STUDY OF LEVODOPA-CARBIDOPA INTESTINAL GEL IN L (P&S Industry Clinical Trial)

    May 1 2009 - May 1 2012

    EFFECT OF COENZYME Q10 IN PARKINSONS DISEASE - PHASE 3 (QE3) (Federal Gov)

    Dec 1 2007 - Nov 30 2011

    A LONGITUDINAL OBSERVATIONAL FOLLOW-UP OF THE PRECEPT STUDY COHORT (POSTCEPT) (Federal Gov)

    Jan 1 2007 - May 31 2011

    TWO YEAR BLINDED ASSESSMENT OPHTHALMOLOGIC SAFETY STUDY OF PRAMIPEXOLE IR VERSUS ROPINIROLE IN EARLY PARKINSON"S (P&S Industry Clinical Trial)

    Jul 8 2005 - Dec 31 2010

    EVALUATION OF BLOOD BIOSPECTROSCOPY AS A NOVEL DIAGNOSTIC TE ST FOR IDIOPATHIC PARKINSON DISEASE (PD BIOSPEC) (Private)

    Aug 4 2009 - Oct 4 2010

    ACUPUNCTURE/MOXIBUSTIONS FOR PEROPHERAL IN PTS WITH HIV (Federal Gov)

    Jul 1 2005 - Jun 30 2009